RxDoctor Payments Data

Walter Kusumoto

Clinical Cardiac Electrophysiology · Chico, CANPI 1619935079

Payments from drug & device makers

$6,682in general payments, 2019–2025

Across 146 payments — averaging $45.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Biosense Webster, Inc.$2K
  • Sanofi-aventis U.S. LLC$543
  • Biotronik Inc.$324
  • Abbott$305
  • E.r. Squibb & Sons, L.L.C.$189
  • plus $512 from 9 others

What the payments were for

  • Travel & lodging$1,65525%
  • Food & beverage$5,01375%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,682 in reported general payments places this provider in the 15th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$1,324,066
Medicare patients
777
Services billed
10,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$201,856
MultaqDronedarone Hcl25$49,423
XareltoRivaroxaban67$48,239
Disopyramide Phosphate39$10,620
Flecainide Acetate135$7,744
Amiodarone Hcl127$5,592
Enoxaparin Sodium112$4,928
SotalolSotalol Hcl46$1,217
Diltiazem 24hr Er (Cd)Diltiazem Hcl39$1,073
Metoprolol Succinate59$869
Diltiazem 24hr ErDiltiazem Hcl27$739
Nadolol12$514
Diltiazem Hcl16$412
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$201,856206 claims
Sanofi-aventis U.S. LLCMultaq$543$49,42325 claims
Johnson & JohnsonXarelto$34$48,23967 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →